AbCellera Biologics (ABCL) Stock
$11.89
+6.78% Close Nov 6
Open interactive chartABCL stock price and performance
ABCL stock closed at $11.89 on Nov 6, 2026. The tables below use that final daily session.
- Last close
- $11.89
- Day range
- $11.20 to $11.98
- 52-week range
- $2.75 to $15.02
- From 52-week high
- −20.9%
- Average volume (50 days)
- 4.4M
- 1 week
- −3.1%
- 1 month
- −1.1%
- 3 months
- +27.3%
- Year to date
- +247.5%
- 1 year
- +153.4%
- 3 years
- +188.5%
- 5 years
- −24.4%
Is ABCL stock in an uptrend?
Yes, ABCL stock is in an uptrend: both Daily Pivot Breakout momentum filters are active, although it does not meet the Minervini Trend Template criteria. Price is above its 200-day moving average.
- Daily Pivot momentum filters
- 2 of 2 active
- 100-day ROC
- +133.5% filter at 40%: active
- 100-day EMA slope
- +132.2% filter at 25%: active
- Trend state
- Uptrend
- Minervini Trend Template
- Not met on the latest scan
- 50-day average
- Below
- 150-day average
- Above
- 200-day average
- Above
- 200-day slope (1 month)
- +14.04%
- ATR (14) % of price
- 8.33%
Momentum filters from the Daily Pivot Breakout indicator: 100-day rate of change and 100-day EMA slope, each against its minimum.
Is ABCL stock in a Stage 2 uptrend?
Yes, ABCL stock is in a Stage 2 uptrend by our Weinstein stage analysis: its price is above a rising 30-week moving average and it is outperforming SPY.
- Weinstein stage
- Stage 2 (advancing)
- 30-week SMA
- $8.40
- 30-week slope (4 weeks)
- +15.61%
- Mansfield RS vs SPY
- 86.87
- Weeks in Stage 2
- 22
Weinstein stage analysis uses weekly closes against the 30-week moving average and Mansfield relative strength versus SPY. See the free Stage 2 stocks screener.
ABCL support and resistance levels
| Level | Price | From close |
|---|---|---|
| Daily Pivot resistance (pivot high) | $13.86 | +16.6% |
| 50-day SMA | $12.28 | +3.3% |
| 21-day EMA | $12.19 | +2.6% |
| 9-day EMA | $12.00 | +1.0% |
| Latest Daily Pivot low | $10.32 | −13.2% |
| 30-week SMA | $8.40 | −29.3% |
| 150-day SMA | $8.24 | −30.7% |
| 200-day SMA | $7.04 | −40.8% |
Levels above the close act as resistance, levels below as support. Last close $11.89.
ABCL breakout and scanner signals
| Scanner | Last signal (free view, 5 sessions late) | Past year |
|---|---|---|
| VCP | None in the last year | 0 |
| RSI Divergence | Sep 24, 2026 (bearish) | 2 |
| Weinstein Stage Analysis | Oct 30, 2026A more recent signal (last 5 sessions) is in the journal. | 103 |
| Daily Pivot Breakout | Sep 28, 2026 | 4 |
| Minervini Trend Template | Oct 29, 2026 | 54 |
| Episodic Pivot | Aug 10, 2026 | 1 |
| Ichimoku TK cross | Oct 19, 2026 (bearish) | 6 |
| 9/21 EMA cross | Oct 28, 2026A more recent signal (last 5 sessions) is in the journal. | 4 |
| Golden / Death Cross | Jun 1, 2026 | 1 |
| RS Rating | Oct 30, 2026A more recent signal (last 5 sessions) is in the journal. | 64 |
ABCL seasonality by month
- Jan+0.3%67% up
- Feb−12.0%0% up
- Mar−5.9%17% up
- Apr−5.6%33% up
- May+5.4%67% up
- Jun+14.5%50% up
- Jul−0.7%50% up
- Aug+10.1%50% up
- Sep+7.6%67% up
- Oct−2.2%50% up
- Nov−0.8%60% up
- Dec−3.1%20% up
Average monthly return over 6+ years of stored daily closes, and the share of years each month closed higher.
ABCL earnings history
| Reported | EPS estimate | EPS actual | Surprise |
|---|---|---|---|
| Aug 5, 2026 | $-0.16 | $-0.18 | −12.5% |
| Jul 16, 2026 | $1.10 | $1.17 | +6.4% |
| May 11, 2026 | $-0.20 | $-0.14 | +30.0% |
| Feb 24, 2026 | $-0.18 | $-0.03 | +83.3% |
ABCL bull and bear case
What looks strong
- Stage 2 uptrend by our Weinstein stage analysis scanner.
- Both Daily Pivot momentum filters are active (100-day ROC 133.5%, 100-day EMA slope 132.2%).
- The 50, 150 and 200-day averages are stacked in uptrend order.
- Price is above a rising 200-day moving average.
- Had a Daily Pivot Breakout on 2026-09-28.
What looks weak
- Does not meet the Minervini Trend Template on the latest scan.
- Price is below the 50-day moving average.
- Short interest is 12.16% of shares outstanding.
- Net income over the last 12 months is negative.
Drawn only from the data on this page. Not a recommendation.
ABCL news and SEC filings, last 30 days
No SEC filings in the last 30 days.
ABCL insider trading and risks
Risk flags from the data
- Short interest is 12.16% of shares outstanding.
- Net income over the last 12 months is negative.
Insider trades: SEC Form 4 open-market purchases and sales.
ABCL valuation and fundamentals
- Market cap
- $3.85B
- Enterprise value
- $3.36B
- P/E (trailing)
- -24.3
- P/E (forward)
- -14.6
- PEG
- -0.49
- Price to sales
- 54.51
- Price to book
- 3.81
- EV to EBITDA
- -16.8
- Gross margin
- –
- Operating margin
- −1,550.0%
- Profit margin
- −248.8%
- Return on equity
- −17.3%
- Revenue (TTM)
- $66.2M
- Revenue growth (quarter, y/y)
- −76.3%
- Cash
- $540.1M
- Debt
- $135.6M
- Beta
- 1.59
| Fiscal year | Revenue | Net income | Free cash flow |
|---|---|---|---|
| 2025 | $75.1M | −$146.4M | −$131.3M |
| 2024 | $28.8M | −$162.9M | −$197.6M |
| 2023 | $38.0M | −$146.4M | −$120.8M |
| 2022 | $485.4M | $158.5M | $203.6M |
ABCL dividends and splits
- Dividend yield
- 0.00%
- Payout ratio
- 0.0%
Who owns ABCL?
- Shares outstanding
- 306.5M
- Float
- 209.0M
- Held by insiders
- +21.7%
- Held by institutions
- +36.8%
- Short interest (% of shares)
- +12.2%
- Days to cover
- 5.7
What does AbCellera Biologics Inc. do?
- CEO
- Dr. Carl L.G. Hansen Ph.D.
- Employees
- 596
- Headquarters
- Vancouver, BC, Canada
- Website
- abcellera.com
